Inducible Nitric Oxide Synthase and PPARγ are Involved in Bladder Cancer Progression

Sandes, Eduardo Omar; Lodillinsky, Catalina; Langle, Yanina; Belgorosky, Denise; Marino, Lina; Giménez, Liliana; Casabé, Alberto Ricardo; Eiján, Ana María

doi:10.1016/j.juro.2012.04.099

Cited by 24 publications

(20 citation statements)

References 28 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increase in inducible nitric oxide synthase (iNOS) expression is associated with early recurrence [114] and metastatic processes [115,116]. Belgorosky et al [117] showed that human colorectal adenocarcinoma cells that express iNOS are more invasive than the non-iNOS-expressing cells.…”

Section: Antimetastatic Effectsmentioning

confidence: 99%

Melatonin-Induced Oncostasis, Mechanisms and Clinical Relevance

Cardinali¹,

Escames²,

Acuña-Castroviejo³

et al. 2016

J Integr Oncol

View full text Add to dashboard Cite

Section: Antimetastatic Effectsmentioning

confidence: 99%

Melatonin-Induced Oncostasis, Mechanisms and Clinical Relevance

Cardinali¹,

Escames²,

Acuña-Castroviejo³

et al. 2016

J Integr Oncol

View full text Add to dashboard Cite

“…Based on the above controversial results, more bladder cancer samples from different races, clinical stages and subtypes are needed to investigate the expression of PPARγ. Regarding cancer prognosis, the results were surprisingly consistent in that amplification of PPARγ mattered greatly in longer survival time and reduced recurrence or progression [12,[14][15][16][17][18].…”

Section: The Expression Of Pparγ In Bladder Cancermentioning

confidence: 64%

The role and function of PPARγ in bladder cancer

Peng¹,

Wang²,

Cheng³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Peroxisome proliferator-activated receptor gamma (PPARγ), a member of the nuclear receptor superfamily, participates in multiple physiological and pathological processes. Extensive studies have revealed the relationship between PPARγ and various tumors. However, the expression and function of PPARγ in bladder cancer seem to be controversial. It has been demonstrated that PPARγ affects the occurrence and progression of bladder cancer by regulating proliferation, apoptosis, metastasis, and reactive oxygen species (ROS) and lipid metabolism, probably through PPARγ-SIRT1 feedback loops, the PI3K-Akt signaling pathway, and the WNT/β-catenin signaling pathway. Considering the frequent relapses after chemotherapy, some researchers have focused on the relationship between PPARγ and chemotherapy sensitivity in bladder cancer. Moreover, the feasibility of PPARγ ligands as potential therapeutic targets for bladder cancer has been uncovered. Taken together, this review summarizes the relevant literature and our findings to explore the complicated role and function of PPARγ in bladder cancer.

show abstract

“…Sandes et al [ 65 ] in their study showed that peroxisome proliferation-activated receptor (PPAR)-gamma controls inducible nitric oxide synthase (NOS) expression at early tumor stages. Decreased levels of PPAR (detected by Western blot) and increased inducible NOS (detected by immunohistochemistry) are associated with BC progression.…”

Section: Resultsmentioning

confidence: 99%

New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer

Ather

Nazim

2015

Korean J Urol

View full text Add to dashboard Cite

Nonmuscle invasive (NMI) urothelial cancer (UC) is associated with varied biological potential. It is characterized by frequent recurrence and progression, which thus worsens the oncological outcome. Nearly three-quarters of NMI UCs recur within 5 years, whereas half can progress during follow-up. Progression is particularly seen in T1 and carcinoma in situ (CIS). Undoubtedly, NMI UC is one of the most expensive cancers to manage. The European Organisation for Research and Treatment of Cancer (EORTC) risk calculator is a commonly used tool for assessing the recurrence and progression potential of a newly diagnosed cancer. The parameters used in the assessment are tumor size and number, pathological stage and grade of the cancer, presence of CIS, and prior recurrence rate. The main advantages of the EORTC tool are its ease of use and the lack of need to run expensive molecular tests. However, reproducibility of pathologic stage and grade is modest, which is a concern to clinicians. Molecular markers have potential for predicting the clinical outcome of NMI UC, given that clinico-pathologic variables are not sufficient for prediction of prognosis in an individual. Significant work has been done in the past 2 decades in understanding the molecular biology of bladder cancer; however, the translational value of this knowledge remains poor. The role for molecular markers in predicting recurrence seems limited because multifocal disease and incomplete treatment are probably more important for recurrence than the molecular features of a resected tumor. Urinary markers have very limited value in prognostication of bladder cancer and are used (mainly as an adjunct to cytology) for detection and surveillance of urothelial cell cancer recurrence. Prediction of progression with molecular markers holds considerable promise. Nevertheless, the contemporary value of molecular markers over clinico-pathologic indexes is limited.

show abstract

Inducible Nitric Oxide Synthase and PPARγ are Involved in Bladder Cancer Progression

Cited by 24 publications

References 28 publications

Melatonin-Induced Oncostasis, Mechanisms and Clinical Relevance

Melatonin-Induced Oncostasis, Mechanisms and Clinical Relevance

The role and function of PPARγ in bladder cancer

New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer

Contact Info

Product

Resources

About